Equities

Immunoprecise Antibodies Ltd

Immunoprecise Antibodies Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.69
  • Today's Change0.015 / 2.22%
  • Shares traded310.61k
  • 1 Year change-66.99%
  • Beta0.2536
Data delayed at least 15 minutes, as of Sep 20 2024 18:23 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The 2 analysts offering 12 month price targets for Immunoprecise Antibodies Ltd have a median target of 6.02, with a high estimate of 9.03 and a low estimate of 3.01. The median estimate represents a 791.58% increase from the last price of 0.675.
High1,237.4%9.03
Med791.6%6.02
Low345.8%3.01

Earnings history & estimates in CAD

On Sep 16, 2024, Immunoprecise Antibodies Ltd reported 1st quarter 2025 losses of -0.150 per share.
The next earnings announcement is expected on Dec 12, 2024.
Average growth rate-4.45%
Immunoprecise Antibodies Ltd reported annual 2024 losses of -0.47 per share on Jul 29, 2024.
Average growth rate+56.07%
More ▼

Revenue history & estimates in CAD

Immunoprecise Antibodies Ltd had 1st quarter 2025 revenues of 5.26m. This missed the 6.75m consensus estimate of the 2 analysts following the company. This was 7.47% below the prior year's 1st quarter results.
Average growth rate-1.35%
Immunoprecise Antibodies Ltd had revenues for the full year 2024 of 24.52m. This was 18.44% above the prior year's results.
Average growth rate+12.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.